Medindia

X

Indian Drug Firm Jubilant Collaborates With Cyclopharm to Market Technegas in the US

by Reshma Anand on  September 14, 2015 at 5:26 PM Corporate News   - G J E 4
Jubilant Life Sciences subsidiary Jubilant DraxImage Inc has signed a deal with  Australia's Cyclopharm to market Technegas, an imaging agent primarily used in Pulmonary Embolism (blockage of lung arteries).
Indian Drug Firm Jubilant Collaborates With Cyclopharm to Market Technegas in the US
Indian Drug Firm Jubilant Collaborates With Cyclopharm to Market Technegas in the US
Advertisement

Jubilant said, "Its wholly-owned subsidiary Jubilant DraxImage Inc has signed a term sheet, subject to satisfactory due diligence and execution of the Definitive Agreement and other necessary approvals, with Cyclopharm Ltd providing DraxImage an exclusive license to market and distribute Technegas in the United States".

Advertisement
"DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain USFDA approval," it added.

Jubilant Life Sciences Chairman Shyam S Bhartia and CoChairman and Managing Director Hari S Bhartia said, "We are pleased to partner with CYC for the clinical development and potential US market introduction of Technegas. This partnership reiterates our commitment to add innovative products in our Radiopharmaceuticals portfolio and will leverage our existing strengths in the nuclear imaging business."

The company said DraxImage will provide at risk up to $4.5 million to fund the USFDA clinical trial currently under development with any additional costs to be funded by both parties equally.

"Upon successful completion of the USFDA trial, DraxImage will be able to convert USFDA trial costs into CYC common stock up to a maximum of 15 percent of the total CYC shareholding," it said.

"DraxImage will pay CYC a 17.5 percent royalty on sale in addition to an agreed margin above the cost of goods sold," it added. At present, Technegas is being sold in 55 countries including EU, Japan and Canada by CYC.

Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All